This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Amgen
Sotio Biotech Inc.
Daiichi Sankyo
AbbVie
Tanabe Pharma America, Inc.
Bayer
Merck Sharp & Dohme LLC
Bolt Biotherapeutics, Inc.
Yuhan Corporation
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
TiumBio Co., Ltd.
Carisma Therapeutics Inc
Taiho Pharmaceutical Co., Ltd.
Novartis
Silverback Therapeutics
AstraZeneca
Mannkind Corporation